Fatty Liver Alliance’s Post

After an announcement on behalf of multinational liver societies last year, non-alcoholic fatty liver disease (NAFLD) is diagnosed and recognized as metabolic dysfunction-associated steatotic liver disease (MASLD). Experts from 50 countries convened in a two-year process that resulted in new categories and terminologies for multiple liver diseases and conditions, which they argued were more accurate and could help the field of liver study get specific about its patient populations. With researchers, medical journals, regulatory bodies and advocacy groups already widely adapting the new terminology for their own uses, STAT notes that the true challenge of the transition will now be educating patients and providers about the names.    While there are no treatments approved for metabolic dysfunction-associated steatohepatitis (MASH; formerly non-alcoholic steatohepatitis) or MASLD, a strong focus on research continues with two new investments from major industry players announced this week alone. #MASH #MASLD #LiverDisease

Love Your Liver Awareness Month is celebrated annually in January to detect early signs and prevent liver diseases. As per the American Liver Foundation, around 33,000 Americans die from liver cancer every year. The risk factors that lead to cirrhosis include obesity, alcoholism, chronic viral hepatitis, unhealthy lifestyle choices etc. Non-alcoholic fatty liver disease (NAFLD) is among the leading causes of liver damage. Accordingly, non-alcoholic steatohepatitis (NASH) is a type of NAFLD that further causes swelling and damage to the liver. However, there are no licensed therapies for NASH, but developing accurate biomarkers is in progress. In this regard, the global non-alcoholic steatohepatitis (NASH) biomarker market is expected to grow with a CAGR of 21.28% during the forecast period 2021-2028. In this Love Your Liver Awareness month, get an in-depth analysis of the NASH Biomarker market: https://lnkd.in/d-W3U-ai . . . Allergan AstraZeneca Bristol Myers Squibb GENFIT #nonalcoholic #steatohepatitis #nash #biomarker #healthcare #wellness #awarenessmonth #liverhealth #marketgrowth #tritonmarketresearch

NEW BLOG: MASLD: The Rebrand You've Never Heard Of When non-alcoholic fatty liver disease changed its name last year, did any one notice? Now termed MASLD, or metabolic dyfunction-associated steatotic liver disease, the rebrand has failed to trigger the wave recognition this condition deserves. In our latest NB blog, Neal Tucker discusses why non-alcoholic fatty liver disease (NAFLD) has changed and the clinical implications, as well as new research examining how existing medications could be utilised to prevent the associated complications in the liver and beyond. Click on the link to read the full article. #PrimaryCare #Hepatology #LiverDisease #HotTopics

In 2023, the landscape of liver disease nomenclature saw significant changes after 200+ experts voted to rename various conditions. 👉 Non-alcoholic Fatty Liver Disease (#NAFLD) became Metabolic Dysfunction-Associated Steatotic Liver Disease (#MASLD) as experts believed the outdated term "non-alcoholic" didn't reflect the disease's complexity. 👉 That means Non-Alcoholic Steatohepatitis (#NASH) became Metabolic Dysfunction-Associated Steatohepatitis (MASH). 👉 A new category, metabolic dysfunction-associated and alcohol-associated liver disease or #MetALD, was also introduced for patients with MASLD consuming over 210 grams of alcohol weekly. The aim was to clarify diseases based on underlying pathology, reflecting the evolving understanding of liver conditions. This activity was not just about names; it's a crucial step to generate more conversation and research for life-limiting conditions that lack treatments. It should be pointed out that not all corners of the liver world agree with this change. Some clinicians and patient advocacy groups have warned that the more complex names make discussion of liver health less accessible to members of the public, and could undo years of educational work. Regardless of your opinion, it's clear these name changes are here to stay, and you can learn more at https://lnkd.in/exjbMu63 #LiverHealth

June 13th marked the Global Fatty Liver Day, highlighting the severe impact of fatty liver disease, which affects 115 million people worldwide. Projected to affect 357 million by 2030, fatty liver disease often goes undiagnosed due to subtle symptoms. It poses major risks for obesity (70% of patients), type 2 diabetes (up to 75%), and hyperlipidemia (20-80%). Left unchecked, it can lead to cirrhosis, liver cancer, and the need for liver transplants. Known as metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe form MASH (metabolic dysfunction-associated steatohepatitis), this condition is life-threatening if not diagnosed early. Often called a 'silent disease,' it shows no specific symptoms in early stages, causing diagnostic delays. gMendel®’s technology could diagnose MASLD or MASH, enabling earlier intervention, reducing patient suffering, and helping health systems save substantial funds that can be allocated elsewhere. #NASH #genetics #genomics #screening #diagnostics #rarediseases #geneticdisorders #healthcare #innovation #healthtech #AI #artificialintelligence #machinelearning #companiondiagnostics #precisionmedicine #VC #venturecapital Novo Nordisk Novo Nordisk Foundation Fatty Liver Foundation Fatty Liver Alliance

Liver disease continued to make headlines this past year, with the renaming of non-alcoholic steatohepatitis (NASH) leading the charge. Now known as metabolic dysfunction-associated steatohepatitis (MASH), the rename has been decades in the making, as scientists and clinicians agreed than the previous name "trivialised the disease and was scientifically inaccurate". They go further: liver disease is incredibly complex, as are the patients and how they present. The old name did a disservice to this complexity and "was not really reflecting the underlying pathology" of the disease. This homogenisation has affected our understanding of liver and, in turn, impacted therapy development. It is hoped that the new name will help break this pattern; marking a major shift in our understanding of the complex drivers of disease and, ultimately, leading to a new era of liver disease therapies. Read the full article in STAT ➡️ https://lnkd.in/e74pcyTS #TeamOchre #biotech #genomics #liverdisease

HCPLive today summarized a recent paper about the utility of using the SAFE score (Steatosis-associated Fibrosis Estimator) for MASLD/MASH assessment and there seemed to be a clear differentiation demonstrated between the MASLD, MetALD, and ALD mortality findings. A quick read and a reminder that alcohol is not a friend of the liver and has consequences. "Individuals without SLD had the best survival, followed by those with MASLD, MetALD, and ALD. After adjustment for age, sex, race-ethnicity, and smoking status, MASLD, MetALD, and ALD were associated with 16%, 33%, and 75% higher mortality, respectively, compared to no SLD. Of note, the ALD subgroup had significantly lower overall survival than the MASLD group (P = .004), but the MetALD subgroup did not (P = .165)." Original paper: "Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score". https://lnkd.in/gVcubiad American Association for the Study of Liver Diseases (AASLD), EASL | The Home of Hepatology, Canadian Association for the Study of the Liver, Global NASH Council, Global Liver Institute, Barcelona Institute for Global Health (ISGlobal)

What impact will a big breakfast have with just a little bit of fruit on the side? Day 6 explores the impact of mixing proteins with fat and fruits. Spoiler: The impact was not huge and was short lived with 30 minutes to peak and 30 minutes longer back to baseline. So, lesson here is mix fruit with proteins and fasts and don't 'over indulge' in the fruit. American Association for the Study of Liver Diseases (AASLD) EASL | The Home of Hepatology European Liver Patients' Association - ELPA LPI LIVER PATIENTS INTERNATIONAL Global Liver Institute, Canadian Association for the Study of the Liver, Prof. Shira Zelber Sagi, Jonathan G. Stine, MD MSc, FACP, Manal Abdelmalek, Rachael Sood RN, MSN, NP-C, CDCES, Arizona Liver Health, Naim Alkhouri, MD, FAASLD, Mazen Noureddin, MD, MHSc, Jörn M. Schattenberg, Zobair Younossi, Global NASH Council, Obesity Matters , Paul Brennan, American Diabetes Association, Barcelona Institute for Global Health (ISGlobal), Jeffrey V. Lazarus, Dexcom, Michael Reiner, MBA

We are excited to announce the publication of our latest article on Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD) in healthy weight individuals. This review sheds light on the growing prevalence of MAFLD among individuals who are not overweight or obese, challenging traditional perceptions of this metabolic disorder. Our comprehensive exploration delves into the genetic, lifestyle, and dietary factors contributing to MAFLD in this population, emphasizing the need for tailored preventive and therapeutic strategies. This shift in perspective underscores the importance of increased awareness and education surrounding liver metabolic disorders in healthy weight individuals. By redefining our understanding of MAFLD, we can better address the unique characteristics of this condition and improve patient outcomes. https://lnkd.in/dXc7Hyjn

https://lnkd.in/gUQD6B6D This article showed the beneficial effect of EVs from Akkermansia muciniphila against Liver fibrosis management.